logo-loader
Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics receives clinical clearance from FDA on its Parkinson's disease therapy

Inhibikase Therapeutics Inc President & CEO Milton Werner sat down with Proactive Investors at the ThinkEquity Conference in New York. The Atlanta-based, privately-held pharma company is focused on developing and commercializing small-molecule kinase inhibitor therapeutics for the treatment of neurological infections and neurodegenerative diseases.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CB2 Insights licenses electronic data capture software to UK...

CB2 Insights (CSE:CBII-OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from Proactive Vancouver to discuss the company doing a deal with MYACCESS Clinics. This will allow CB2’s software to capture comprehensive data sets related to patient health and treatment histories and manage ongoing...

1 day, 9 hours ago

2 min read